Evidence map›Paper›PMID 41654661›Full record

ArticleAnnals of surgical oncology2026

Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen.

Natasha J Stonebanks Cuillerier, Hamda Almarzooqi, Victor Villareal-Corpuz, Sarah Sabboobeh, Ipshita Prakash, Mark Basik, Jean Francois Boileau, Karyne Martel, Sarkis Meterissian, Michael Pollak and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Natasha J Stonebanks CuillerierDepartment of Surgery, McGill University Medical School, Montreal, QC, Canada.
Hamda AlmarzooqiDepartment of Surgery, McGill University Medical School, Montreal, QC, Canada.
Victor Villareal-CorpuzStroll Cancer Prevention Centre, Jewish General Hospital, Montreal, QC, Canada.
Sarah SabboobehDepartment of Surgery, McGill University Medical School, Montreal, QC, Canada.
Ipshita PrakashDepartment of Surgery, McGill University Medical School, Montreal, QC, Canada.
Mark BasikDepartment of Surgery, McGill University Medical School, Montreal, QC, Canada.
Jean Francois BoileauDepartment of Surgery, McGill University Medical School, Montreal, QC, Canada.
Karyne MartelDepartment of Surgery, McGill University Medical School, Montreal, QC, Canada.
Sarkis MeterissianDepartment of Surgery, McGill University Medical School, Montreal, QC, Canada.
Michael PollakStroll Cancer Prevention Centre, Jewish General Hospital, Montreal, QC, Canada.
Stephanie M WongDepartment of Surgery, McGill University Medical School, Montreal, QC, Canada. sm.wong@mcgill.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndocrine prevention is a well-established preventative strategy for women with high-risk lesions (HRL). The objective of the study was to evaluate factors associated with endocrine prevention adherence in this patient population. PATIENTS AND

methodsWe performed a retrospective cohort study of all women referred for atypical ductal and lobular hyperplasia (ADH/ALH) and lobular carcinoma in situ (LCIS) between 2019 and 2025. Data pertaining to eligibility, initiation, and adherence to endocrine prevention were extracted with univariate analyses performed to evaluate factors associated with adherence.

resultsAmong 200 female patients with HRL, 112 (56%) had ADH, 72 (36%) had ALH, and 16 (8%) had classical LCIS. The median age was 55 years (IQR 50-62 years), with 126 (63%) patients accepting a prescription for endocrine prevention. Low-dose tamoxifen was the most common regimen prescribed (65.1%), compared with regular-dose tamoxifen (13.5%), raloxifene (16.7%), and aromatase inhibitors (4.8%). At a median follow-up of 37 months (IQR 18-49 months), 83 of 126 women (65.9%) initiated endocrine prevention and 72 (57.1%) remained adherent. Age (67.7% 51-60 years versus 47.1% < 50 years, p = 0.046), family history of breast cancer (71.0% vs. 52.6%, p = 0.048), and awareness of endocrine prevention (75.0% vs. 52.0%, p = 0.03) were significantly associated with adherence. Of 50 patients who initiated tamoxifen 5 mg, 46 (92%) remained adherent, and of 13 women who completed at least 3 years of therapy, 9 (69.2%) elected to complete a total 5 year course of low-dose tamoxifen.

conclusionsAdherence to endocrine prevention is high in women who initiate medication, with few discontinuing due to side effects.

Indexed as

Antineoplastic Agents, HormonalBreast Carcinoma In SituBreast NeoplasmsCarcinoma, LobularHyperplasiaTamoxifenAromatase InhibitorsFemaleFollow-Up StudiesHumansMedication AdherenceMiddle AgedPrognosisRetrospective StudiesAntineoplastic Agents, HormonalAromatase InhibitorsTamoxifenAtypical ductal hyperplasiaAtypical lobular hyperplasiaBreast cancer risk reductionChemopreventionEndocrine preventionLobular carcinoma in situTamoxifen

Identifiers

PMID41654661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.